Clinical Trial

Impact of Oral Supplementation With Bioactive Collagen Peptides and Other Functional Ingredients

Study acronym: Maicol
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Genitourinary Syndrome of Menopause (GSM), characterized by vaginal dryness, pain, urinary incontinence, and other symptoms, can be mitigated through both hormonal and non-hormonal treatments. Collagen peptides have shown promising results in improving skin, cartilage, and exhibiting antioxidative activities in studies. This study evaluates changes of quality of life and sexual function, related to vulvovaginal atrophy (VVA) and initial urinary incontinence (UI) in women with GSM symptoms, with the intake of a daily oral food supplement containing 2.5 g of Bioactive Collagen Peptides (BCP®) and other functional ingredients over a 16-week period . This can represent a new therapeutic option for these patients, particularly when hormonal therapy is not an option.
Trial Details
NCT Number NCT07151482
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Genitourinary Syndrome of Menopause
Enrollment 43 participants
Start Date 2025-09-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-09-03